News stories about Edge Therapeutics (NASDAQ:EDGE) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Edge Therapeutics earned a news impact score of 0.16 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.3282921841741 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:
- Global Angiopoietin 1 Receptor Market 2017 – Aerpio Therapeutics Inc., Deciphera Pharmaceuticals (culthub.com)
- Global Primary Biliary Cirrhosis Drug Market 2017 – AlbireoPharma, CymaBay Therapeutics, Inc (canadianbusinesstribune.com)
- Edge Therapeutics (EDGE) vs. Its Competitors Head-To-Head Survey (americanbankingnews.com)
- Indian Facial Injectors Market-Leading Players Resort to Dealmaking to Gain Competitive Edge (culthub.com)
- Head to Head Comparison: Edge Therapeutics (EDGE) and Its Rivals (americanbankingnews.com)
Shares of Edge Therapeutics (EDGE) opened at $9.45 on Friday. The company has a debt-to-equity ratio of 0.20, a current ratio of 8.34 and a quick ratio of 8.34. Edge Therapeutics has a 12 month low of $7.30 and a 12 month high of $13.40. The company has a market cap of $288.53, a price-to-earnings ratio of -6.06 and a beta of 2.52.
A number of research firms have recently commented on EDGE. BidaskClub lowered shares of Edge Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, December 12th. Zacks Investment Research raised shares of Edge Therapeutics from a “sell” rating to a “buy” rating and set a $12.00 price objective on the stock in a research note on Monday, November 6th.
In related news, insider Brian A. Leuthner sold 7,500 shares of the stock in a transaction on Tuesday, December 5th. The shares were sold at an average price of $9.86, for a total transaction of $73,950.00. Following the transaction, the insider now directly owns 95,236 shares of the company’s stock, valued at $939,026.96. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Brian A. Leuthner sold 2,500 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $10.81, for a total transaction of $27,025.00. Following the transaction, the chief executive officer now directly owns 110,236 shares in the company, valued at $1,191,651.16. The disclosure for this sale can be found here. Over the last three months, insiders have sold 35,861 shares of company stock worth $378,035. 36.19% of the stock is owned by insiders.
COPYRIGHT VIOLATION NOTICE: This story was first published by Community Financial News and is owned by of Community Financial News. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://www.com-unik.info/2017/12/29/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-edge-therapeutics-edge-share-price.html.
About Edge Therapeutics
Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.
Receive News & Ratings for Edge Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.